Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
MAXCYTE, INC. (MXCT)
|
Add to portfolio |
|
|
|
| Price: |
$10.11
| | Metrics |
| OS: |
103.5
|
M
| |
-14
|
% ROE
|
| Market cap: |
$1.05
|
B
| |
-20
|
% ROIC
|
|
Net cash:
|
$216
|
M
| |
$2.09
|
per share
|
|
EV:
|
$830
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($36.9)
|
M
| |
|
|
|
EBIT
|
($40.6)
|
M
| |
|
|
| EPS |
($0.32)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 28.7 | 21.6 | 15.5 | 13.3 |
| Revenue growth | 33.3% | 39.6% | 16.6% | |
| Cost of goods sold | 5.1 | 3.6 | 2.8 | 2.5 |
| Gross profit | 23.7 | 17.9 | 12.7 | 10.8 |
| Gross margin | 82.3% | 83.1% | 82.1% | 81.1% |
| Sales and marketing | 18.7 | 13.0 | 8.3 | 7.9 |
| Research and development | 19.5 | 15.4 | 17.7 | 17.6 |
| General and administrative | 25.8 | 18.7 | 7.4 | 5.6 |
| EBIT | -27.1 | -17.7 | -10.8 | -12.4 |
| EBIT margin | -94.2% | -81.9% | -69.8% | -93.7% |
| Pre-tax income | -23.6 | -19.1 | -11.8 | -12.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -23.6 | -19.1 | -11.8 | -12.9 |
| Net margin | -82.0% | -88.5% | -76.5% | -97.3% |
| |
| Diluted EPS | ($0.23) | ($0.21) | ($0.17) | ($0.23) |
| Shares outstanding (diluted) | 101.7 | 90.6 | 69.5 | 56.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|